id	document	topic	topic_prob	topic_word	plot_x	plot_y	td_x	td_y	td_z
0	0	Hazard Ratio  (and 95% Confidence Intervals)  in Univariate and Multivariate Analysis of Predictors of Major Cardiac Events  (Cardiac Death or Worsening of Heart Failure Leading to Heart Transplantation)	0	16	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	9.664474	8.992035	103.58746	72.253586	5.65633
1	1	Left Ventricular and Right Ventricular Ejection Fractions, Left Ventricular and Right Ventricular Mean Phases, Left-to-Right Mean Phase Difference  (L-RMP)  and Phase Standard Deviations for Both Ventricles in 30 Cases of Left Sided WPW legend	0	25	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	23.601093	-15.2017975	31.781635	89.92669	-82.63583
2	2	Partial Regression Coefficients  (All Subjects, n = 262)  for Forward Stepwise Linear Regression for Dependent Variables Augmentation Pressure and Augmentation Index    legend	0	12	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	11.646137	0.97763896	20.661259	124.87336	-45.061954
3	3	Left Ventricular  (LVEF)  and Right Ventricular  (RVEF)  Ejection Fractions, Left Ventricular  (LVMP)  and Right Ventricular  (RVMP)  Mean Phases, Left-to-Right Mean Phase Difference  (L-RMP)  and Phase Standard Deviations  (LVPSD and RVPSD)  for Both Ventricles in 14 Cases of Right Sided WPW legend	0	31	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	23.60182	-15.202716	24.231483	92.08438	-102.17858
4	4	Predictors of Mortality by Multivariable Analysis: Variables Are Shown in the Order They Entered a Stepwise Cox Regression Model	0	11	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	8.242556	3.2811804	-146.37094	8.817643	-81.40019
5	5	Logistic Regression Models for Pre- and Post-Transplant Predictors for Normalization of Left Ventricular Ejection Fraction  (LVEF 50%)  in the Post-Transplant Period  (Reference Group: Group With LVEF 50% in the Post-Transplant Period)	0	21	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	13.225922	-0.97631407	107.89072	130.8689	-55.291992
6	6	Results of Survival Analysis  (Cox Proportional Hazards Model)  for the Combined End Point: Cardiac Mortality + Urgent Heart Transplantation + Readmission for Congestive Heart Failure	0	17	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	5.6147494	8.802479	124.24056	16.723385	-6.6259217
7	7	Impact of Normal Versus Reduced Left Ventricular Ejection Fraction on the Mortality of Congestive Heart Failure Cases: Results of Cox Proportional Hazards Regression Models	0	17	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	4.419053	8.055964	127.55127	27.194212	-41.71926
8	8	Description of the Left Ventricular Ejection Fraction  (LVEF%)  at Different Time Periods: At the Time of Transplant Evaluation, While on the Waiting List to be Transplanted, and During the Follow-Up After Kidney Transplantation	0	15	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	12.462818	-1.2678202	96.68417	108.18609	-65.152824
9	9	Univariate Cox Regression Analysis and Cox Proportional Hazards Analysis of Predictors of Cardiac Death legend	0	10	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	9.879312	5.7678313	45.471752	-115.20811	79.15913
10	10	Gender-Specific Mean and Standard Deviation of LV Mass, End-Diastolic Volume, Stroke Volume, Ejection Fraction, and Cardiac Output by Cardiac MRI in MESA Participants	0	15	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	7.941769	-17.331753	104.30818	59.27679	-113.74892
11	11	Results of Multiple Logistic Regression Analysis: Final Significant Variables in Equation Using Forward Stepwise Selection  (Wald)	0	12	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	10.830174	2.0605228	27.68589	90.90104	-29.683985
12	12	Multivariable Cox Proportional Regression Analysis Showing Significant Predictors of Outcome  (Death, Heart Transplant, or Left Ventricular Assist Device Implantation)  in Cardiac Resynchronization Therapy Patients	0	14	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	9.8792095	7.0329175	133.00696	81.86411	-82.76946
13	13	Multiple regression analysis using Cox's proportional hazards model to determine the influence of individual variables on survival in hypopituitarism	0	11	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	8.23823	6.729453	55.159103	54.554237	-10.591427
14	14	ORs and RRs  (95% Confidence Intervals)  for Other Correlates of Preserved Left Ventricular Systolic Function in Order of Entry Into the Full Logistic Model	0	9	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	5.918713	-1.0695376	63.385067	39.046913	-106.4544
15	15	Multiple Regression Analysis of Variables Associated With CD40L Levels; Entire Model  (Regression Summary for Dependent Variable: R2= 0.60, F = 5.58; p < 0.00005)  and Final Model With Stepwise Method	0	10	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	9.484116	2.6230102	119.05351	71.02622	-39.873447
16	16	Final multivariable Cox proportional hazards model of time to first late seizure in the derivation cohort	0	10	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	4.6279173	5.543165	45.714924	1.6905954	-28.640127
17	17	Univariate and Multivariate Linear Model of Left Ventricular End-Diastolic Volume Index in 113 Patients With CHF legend	0	11	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	7.4898906	-1.3650845	-43.13407	-171.4404	12.783203
18	18	Logistic Regression Multivariate Independent Predictors of Spontaneous Conversion to Sinus Rhythm	0	8	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	5.2321568	1.40721	-23.058233	113.11043	19.314796
19	19	Table of Regression Coefficients From a Multivariate Linear Regression Model for LV Mass-to-Volume Ratio	0	10	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	7.2899227	1.1928077	68.7165	42.917126	-67.24173
20	20	Univariate and Multivariate Cox Proportional Hazard Analyses for the Identification of Patients With Chronic Heart Failure at Risk for Cardiac Events	0	9	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	8.08969	8.670753	87.049995	57.22627	28.088205
21	21	Variables Independently Associated With In-Hospital Mortality Adjusted by Risk in a Multivariable Logistic Regression Model and a Multilevel Model, With Odds Ratio and 95% Confidence Intervals for Each Variable	0	15	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	7.2660847	2.8019667	104.95518	47.442387	-69.40598
22	22	Cox proportional hazards regression model for individual factors affecting graft failure in first-time recipients of kidneys from cardiac-death donors, adjusted for age of donors and recipients, and cold ischaemic time	0	19	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	4.308547	11.961737	150.47363	-12.177003	-110.03043
23	23	Final Multivariable Cox Proportional Hazards Model  (Global Chi-Square of the Model = 1,146.1, p < 0.001)	0	8	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	5.308862	5.327763	58.380104	25.157219	-34.13797
24	24	Multivariate Stepwise Cox Regression Analysis of Potential Risk Variables in Order to Detect Independent Predictors of Cardiac Death or Acute Myocardial Infarction at 30 Days legend	0	11	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	10.479092	4.2256083	100.50832	122.77673	-8.8561
25	25	Intervals Measured During Ventricular Tachycardia, Responses to Pacing During Ventricular Tachycardia and Sinus Rhythm and Presence of Isolated Diastolic Potential During Sinus Rhythm	0	15	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	5.6652284	0.48168495	39.63435	39.94816	-169.96638
26	26	Impact of Congestive Heart Failure on Mortality: Results of Multivariable Cox Proportional Hazards Regression Models legend	0	12	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	5.1367493	7.6430206	79.56394	87.805275	-28.497307
27	27	Multivariable Analysis for Independent Predictors of Survival in HFpEF Patients  (Cox Proportional Hazard Model)	0	9	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	6.603587	6.432061	84.622955	4.605337	22.487045
28	28	Multiple Linear Regression Analysis Assessing the Independent Influence of Different Variables on Natriuretic Peptides	0	8	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	9.359673	1.0741712	44.650543	66.56165	-47.03514
29	29	Multiple Regression Analysis of the Relationship Between Left Ventricular Mass Index and Other Variables for the Entire Group	0	11	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	9.847215	0.05516863	128.05669	39.448967	30.48513
30	30	Cox proportional hazards regression model for graft failure in first-time recipients of kidneys from cardiac-death donors, adjusted for age of donors and recipients, and cold ischaemic time	0	18	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	4.3096724	11.959738	-108.78321	-16.362438	135.38136
31	31	Partial Correlation Coefficients  (r) , Controlled for Age, of Body Size, Body Composition and Blood Pressure With Unindexed and Indexed Left Ventricular Mass  (LVM)	5	9	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	16.377674	-19.135729	13.993134	90.5244	-164.43631
32	32	Multiple Linear Regression Analysis Results With Augmentation Index as the Dependent Variable  a	0	9	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	10.248336	0.93792963	-81.12543	64.620964	-49.717613
33	33	Multivariate Cox Proportional Hazards Regression Model of Significant Predictors of Death or Heart Failure	0	10	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	7.4635525	5.5610213	84.877144	61.802364	-22.862207
34	34	Results of Multivariable Modeling: Hazard Ratios, 95% Confidence Intervals and p Values for Significant Multivariable Predictors of Outcome in Models That Incorporate Echocardiographic, Clinical and Hemodynamic Variables	0	15	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	6.406329	4.4255433	90.66761	36.830265	-37.72038
35	35	Differences Among End-Diastolic Volume, End-Systolic Volume, Ejection Fraction and Left Ventricular Mass as Revealed on Cine MRI and Real-Time MRI legend	0	15	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	8.434353	-2.2116344	127.388725	-13.289686	-69.38082
36	36	Analysis of Significance and Prognostic Value of End-Diastolic Volume, Stroke Volume, Left Ventricular Ejection Fraction and Heart Rate Obtained During Dobutamine Infusion  a	0	14	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	8.882921	-2.5902681	76.14032	85.02048	-107.98202
37	37	Multivariate Logistic Regression Analyses to Assess the Predictive Value of Electrocardiographic Strain for the Presence of LVH, Abnormal LV Geometry and Abnormal LV Midwall Function in Patients With and Without Evident CHD    legend	5	9	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	3.9819508	0.73595804	52.15461	127.920876	-9.920168
38	38	Final Multivariable Cox Regression Model of Predictors of Death Among 1,953 Children With DCM Not Undergoing Heart Transplantation	0	9	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	8.301655	4.9083505	84.78592	6.7218146	-20.989653
39	39	Multivariable Analysis for Independent Predictors of Survival in HFpEF Patients With CAD  (Cox Proportional Hazard Model)	0	10	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	6.603587	6.432061	84.622955	4.605337	22.487045
40	40	Cox proportional hazard analysis for the effect of covariates on survival in patients with chronic heart failure  (SOLVD)	0	7	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	7.146009	8.243703	-25.19229	18.372883	-11.761292
41	41	Multiple Linear Regression Analysis of Clinical and Hemodynamic Variables and Follow-Up Left Ventricular Ejection Fraction  legend	0	10	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	10.38973	-0.5529752	69.68574	84.682	-67.74736
42	42	Odds Ratios  (With 95% Confidence Intervals)  for Univariate Predictors of Mortality and for Those Same Predictors Together With Log10Troponin in Bivariate Models	0	9	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	5.9544754	3.144794	96.99982	5.5332994	-52.156425
43	43	Multivariate Cox Proportional Hazards Models for Prediction of Time to Recurrence legend	0	7	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	4.488573	4.8230643	15.978383	-60.169617	-96.65552
44	44	Univariate and Multivariate Analysis of Predictive Variables for log Vo 2max/kg2/3	0	5	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	2.865608	0.23841712	-62.73019	-144.40193	-164.29742
45	45	Cox Proportional Hazard Models for MR-proANP and NT-proBNP to Predict Survival in Different Subgroups of Patients With Chronic Heart Failure  (Derivation and Validation Samples Combined)	0	16	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	6.9267526	9.625693	90.773186	32.757385	3.598703
46	46	Computer Directed and Clinically Directed Stepwise Multiple Logistic Regression and Cox Proportion Hazard Analysis of Determinants of Hard Events in Medically Treated Patients legend	0	12	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	11.644342	7.1801596	52.908276	84.47861	3.2905886
47	47	Multivariate analysis of predictors of ventricular tachycardia, sudden death, and atrial flutter/fibrillation after repair of tetralogy of Fallot	0	13	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	12.301235	4.8814898	85.748795	38.511967	-150.18767
48	48	Unadjusted Cox Proportional Hazards Regression Analysis of Predictors of Death Among 1,953 Children With DCM Not Undergoing Heart Transplantation	0	11	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	8.9257345	5.4981384	88.962265	-66.91404	-89.85276
49	49	Multivariate Cox Regression Analyses for Peak Vo 2and Ve/Vco 2Slope	0	5	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	2.673183	0.77788574	-42.57802	26.266237	-98.06517
50	50	Potential effect of the internet on physical activity interventions  (based on effect estimates from web-based physical activity interventions and other physical activity interventions)  and the potential effect of mobile phones on physical activity interventions  (based on effect estimates from telephone-based physical activity interventions and from other physical activity interventions) , by country income	1	36	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-15.383671	0.5561474	45.63049	-75.58957	-66.93554
51	51	Analysis of trends from 19992002 and 200306 for government health expenditure as source  (GHE-S) ; share of general government expenditure spent on health  (GHE-S/GGE) ; share of gross domestic product  (GDP)  spent by government  (GGE/GDP) ; and GDP	2	17	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	-6.8240457	8.9722805	64.68869	-1.2504975	-131.0327
52	52	Changes between 2012 and 2017 in the modern contraceptive prevalence rate  (mCPR) , unmet need for modern methods, demand satisfied with modern methods, and the number of women of reproductive age who are married or in a union using modern methods of contraception	1	20	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-24.22217	-2.4032218	-88.48458	14.903282	-95.47482
53	53	Postprandial Changes of Nitrates/Nitrites, Lipoperoxides, and 8-epi Prostaglandin Plasma Levels After the Ingestion of a Phenol-Rich Olive Oil Meal  (400 ppm)  as Compared to a Low Phenol Olive Oil Meal  (80 ppm)	1	17	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-20.535402	-16.032675	15.232465	-103.41379	-31.720966
54	54	Analysis of association between receipt of financial assistance from Janani Suraksha Yojana and intervention coverage and health outcomes by use of two analytical approaches by high-focus, northeast, and non-high-focus states	1	16	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	29.027655	-3.332284	49.988358	-3.5004907	-67.41207
55	55	Number  (millions)  of women with an unmet need for modern methods and proportion of those wanting to avoid pregnancy with unmet need for modern methods, by region and subregion and by country income, in 2003, 2008, and 2012	1	19	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-22.003387	-1.9434241	-1.6289747	-62.6863	-60.62882
56	56	Aggregate official development assistance to maternal, newborn, and child health, to child health per child, and to maternal and newborn health per livebirth in 2005 and 2006, and percentage change for the two categories between 2003 and 2006	2	18	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	25.173565	-6.900714	75.22054	-37.2812	87.17767
57	57	Official development assistance to child health per child and to maternal and neonatal health per livebirth, total to maternal, newborn, and child health in 2007 and 2008, and trends statistics, 200308	2	17	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	25.073002	-7.0018992	53.546562	-43.262226	96.23089
58	58	Official development assistance to maternal, newborn, and child health by aid modality and project purpose for the 68 Countdown priority countries, 200308	2	13	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	23.40715	-5.540627	-46.149387	7.2220025	-68.59408
59	59	Official development assistance to maternal, newborn, and child health to the 74 Countdown priority countries by type of aid and purpose of projects between 2003 and 2010	2	13	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	22.787165	-5.3685246	89.274796	-33.73562	121.91098
60	60	Effects of varying selected assumptions on the estimated additional annual running costs of providing child survival interventions at universal coverage, from reported levels in 2000  (US$5134 million)	1	18	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-16.865131	-2.041004	51.619507	-44.036045	-91.43368
61	61	Time-series cross-sectional regression results for government health expenditure as source  (GHE-S)  as a share of gross domestic product  (GDP)  for countries in Global Burden of Disease developing regions based on the Arellano-Bover/Blundell-Bond model	2	19	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	-6.1083817	8.677727	48.409397	-2.7652645	-108.98253
62	62	Modern contraceptive prevalence rate  (mCPR) , unmet need for modern methods, and demand satisfied with modern methods in 2017 for 68 Family Planning 2020 countries	1	16	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-24.04324	-2.4135795	-77.5276	-1.7598066	-104.884926
63	63	Numbers and incident rate ratios for recorded referrals and identifications of women experiencing domestic violence in general practice and domestic violence referrals received by specialist agencies, 12 months after intervention	2	11	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	0.69600993	4.865373	-5.8827567	-157.03566	-8.248065
64	64	Number  (millions)  of women using modern methods and proportion of those wanting to avoid pregnancy using modern methods, by region and subregion and by country income in 2003, 2008, and 2012	1	15	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-21.857317	-1.4505831	-10.050128	-49.60111	-76.03896
65	65	Estimated annual running costs of providing preventive interventions for child survival at 2000 coverage levels and universal coverage levels	1	14	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-17.2286	-2.6600149	51.143284	-60.395973	-111.85095
66	66	Antipneumococcal IgG antibody responses 1 month after booster vaccination with PHiD-CV and DTPa-HBV-IPV/Hib with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	2.9333858	-19.604252	-40.24189	-71.755875	-98.539154
67	67	Official development assistance to maternal, newborn, and child health by type and source of aid flow for the 68 Countdown priority countries, 200308	2	12	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	22.480606	-6.2936068	-21.621052	30.03397	-70.086494
68	68	Health service resource use: mean  (SD)  resource use per patient and unit costs of resource items by type of care  (UK, 2009 prices)	1	11	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-3.7413247	-3.3574746	-27.6529	-118.76185	-138.18764
69	69	Antibodies to neuronal antigens in cerebellar syndromes   Sera were screened by routine immunohistochemistry on frozen sections of rat cerebellum and positive staining patterns1 were confirmed, as appropriate, by western blotting on rat cerebellar extracts or recombinant Hu or Yo polypeptides. VGCC antibodies were measured by immunoprecipitation of 125I--conotoxin MVIIC-labelled VGCCs extracted from human cerebellum,  2   and antibodies to glutamic acid decarboxylase measured with a commercial kit  (RSR Ltd, Cardiff, UK) .	3	34	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-1.0354756	4.40404	-65.114105	-27.71023	-144.43314
70	70	Direct health-care costs attributable to physical inactivity paid by the public sector, private sector, and households, by country and WHO region  (in 1000 Int$, 2013)	1	15	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-2.5905046	3.1024709	-5.611196	-39.483887	-129.07603
71	71	Ranking of research priorities for development of interventions to reduce stillbirths in low-income and middle-income countries	1	8	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-17.567951	2.0229394	48.62669	133.33788	-80.37503
72	72	Rankings of research priorities for implementation of interventions to reduce stillbirths in low-income and middle-income countries by 2015	1	9	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-17.549055	2.0284474	48.80664	-50.632202	-40.071854
73	73	Worldwide official development assistance to maternal, newborn, and child health by type of aid and purpose of projects between 2003 and 2006	2	11	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	23.217207	-4.6468215	-96.359474	-88.71628	-73.191216
74	74	Official development assistance to reproductive health to the 74 Countdown priority countries by type of aid and purpose of projects, 200910	2	10	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	22.002691	-5.023485	-21.133595	0.111343026	-82.90759
75	75	OPA responses 1 month after booster vaccination with PHiD-CV and DTPa-HBV-IPV/Hib with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)	6	11	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	3.0362647	-19.355001	-51.574066	-94.32174	-98.644806
76	76	Estimated number of neonatal deaths in 75 countries by region that could be averted by universal  (99% coverage)  delivery of all  *   evidence-based interventions	1	11	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-14.34912	0.52770984	29.607904	-96.820984	-77.35408
77	77	Percentage distribution of women in developing countries using modern contraceptives, by type of method, region and subregion, and country income, in 2003, 2008, and 2012	1	9	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-21.332338	-0.514314	-27.210548	-34.41269	-88.15214
78	78	Antipneumococcal IgG antibody responses 1 month after primary vaccination with PHiD-CV, DTPa-HBV-IPV/Hib, and human rotavirus vaccine with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)	6	15	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	2.6721876	-20.79381	1.3075418	4.0173383	-153.97328
79	79	Estimated annual running costs of delivering treatment interventions for child survival at 2000 coverage levels and universal coverage levels	1	14	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-17.29651	-2.7588596	-66.56222	2.336047	172.13724
80	80	Neglected low-cost opportunities and high-cost interventions in south Asia and sub-Saharan Africa	1	9	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-3.718594	1.7654847	24.069647	-27.651438	-51.79879
81	81	Estimates and uncertainty intervals of the number of MWRA  (millions)  aged 1549 years, for total contraceptive use, unmet need, total demand, and unmet need for modern methods, for 2010 and 2015	1	13	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-22.07823	-3.2290306	-2.0258229	-70.78372	-35.175457
82	82	Serum-antibody concentrations against capsular polysaccharide of Haemophilus influenzae type b  (PRP)  in Chilean infants given different primary immunisation regimens of PRP-T and PRP-CRM197 conjugate vaccines	6	15	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-1.3042781	1.3570151	-85.81644	-66.032684	-154.2278
83	83	Estimated odds ratios  (95% CI)  for prevalence of respiratory symptoms and decrease in peak expiratory flow  (PEF)  with increase in air pollutants in children with BHR and relatively low serum total IgE  (n=67)	1	15	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-11.9038925	20.042593	136.7696	-31.396723	76.057625
84	84	Official development assistance to maternal, newborn, and child health by donor for the 68 Countdown priority countries, 200308	2	10	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	23.113148	-6.2968717	-25.046139	10.221918	-51.7991
85	85	Change in numbers of sexual partners and prevalence of sexual practices, behaviours, and attitudes in Natsal-3 and Natsal-1 relative to Natsal-2, by sex	1	13	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	0.008478016	0.61970353	190.27519	-29.286732	13.944268
86	86	Birthweights of children born to mothers with chronic pregnancy-associated P falciparum malariaaccording to mothers' plasma IgG concentration with specificity for type of VSA	1	11	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	8.490994	12.735293	8.046009	96.78699	3.2564626
87	87	Estimated odds ratios for prevalence of respiratory symptoms and decrease in peak expiratory flow  (PEF)  with increase in air pollutants in children without BHR but with relatively high serum total IgE  (n=104)	1	17	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-12.01012	20.433084	1.4944384	50.464275	-135.19801
88	88	AUC of the Different Parameters After the Ingestion of a Phenol-Rich Olive Oil Meal  (400 ppm)  as Compared to a Low Phenol Olive Oil Meal  (80 ppm)	1	11	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-20.534351	-16.026335	-38.224716	58.473858	-108.02334
89	89	Estimated preterm birth rates and total number of preterm births for 2010, by Millennium Development Goal region	1	7	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-8.6584015	-12.076055	51.086884	-106.02225	-127.84735
90	90	Serum concentrations of antibodies against individual pneumococcal vaccine serotypes and protein D one month after the third protein D conjugate vaccine dose and before and 1 month after booster vaccination*	6	16	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	4.4226766	-20.407314	-78.238594	-86.4472	-115.98626
91	91	Estimated odds ratios  (95% CI)  for prevalence of respiratory symptoms and decrease in peak expiratory flow  (PEF)  with increase in air pollutants in children with BHR and relatively high serum total IgE  (n=121)	1	17	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-12.01012	20.433084	1.4944384	50.464275	-135.19801
92	92	Antibody responses after primary vaccination with PHiD-CV, DTPa-HBV-IPV/Hib, and human rotavirus vaccine with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)	6	14	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	2.0787945	-21.016867	-54.39357	-70.18282	-72.56728
93	93	Percentage of ever-partnered women reporting selected symptoms of ill health  *   according to experience of physical or sexual violence, or both, by an intimate partner, by site	1	14	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-0.4543475	2.434943	-55.58724	-134.02652	0.7803501
94	94	Median price ratios  *   of originator brands and lowest-priced generics in the private sector, and of lowest-priced generics in the public sector, by WHO Region	1	16	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-3.5157309	3.7775009	5.112251	-63.185272	-146.95416
95	95	Antibody responses after booster vaccination with PHiD-CV and DTPa-HBV-IPV/Hib with or without prophylactic antipyretic administration  (ATP immunogenicity cohort)	6	11	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	2.3297105	-18.997578	-25.817379	-90.96351	-85.75345
96	96	Comparison of mean adjusted death rate, mean number of acute-care hospital beds, mean number of surgeons, and mean total Medicare-enrollee reimbursements by regions of high, middle, and low adjusted surgical intensity at the end of life	1	16	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-8.250326	-6.051169	51.264557	76.87509	43.634293
97	97	OPA responses 1 month after primary vaccination with PHiD-CV, DTPa-HBV-IPV/Hib, and human rotavirus vaccine with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)	6	14	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	2.0602694	-20.466507	-66.7141	-58.70279	-96.02345
98	98	Proportion of women with polycystic ovaries, mother's weight, body-mass index, and mean concentrations of plasma LH and testosterone according to birthweight among women whose mothers' weight in pregnancy was above 58 kg  (median)	1	17	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	8.837731	13.358586	-10.182624	80.178085	14.84843
99	99	Analysis of association between receipt of financial assistance from Janani Suraksha Yojana and intervention coverage and health outcomes by use of three analytical approaches at the national level	1	14	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	29.017776	-3.3359551	20.902262	-63.642384	174.28773
100	100	Treatment efficacy at week 36 for the modified intention-to-treat population in the open-label period and at week 88 for the modified intention-to-treat subpopulations in the double-blind period	6	17	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-17.807772	12.390129	-9.899911	-60.5823	5.320809
101	101	Overview of treatment-emergent adverse events grade 12  (occurring in 10% of patients) , all grade 3 and worse adverse events, and all serious adverse events	6	14	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-27.311901	16.186436	39.75065	172.92422	-18.467102
102	102	Most common adverse events, grade 3 or worse adverse events, and serious adverse events during the overall treatment period  (neoadjuvant and adjuvant)	6	14	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-26.28798	16.45642	-22.824	-99.18817	146.18619
103	103	Drug-related adverse events occurring at any grade in at least 10% of patients, or at grade 3 or higher in any patients in either group, from the start of treatment to 30 days after the end of treatment  (safety population)	6	17	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-30.303911	16.434568	-86.78979	-69.546326	69.6129
104	104	Drug-related treatment-emergent adverse events by MedDRA system organ class and preferred term in the first on-study chemotherapy cycle  (safety population)	6	16	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-23.330067	8.52554	-8.554949	-133.59236	31.924837
105	105	Treatment-emergent adverse events and treatment-emergent drug-related adverse events  *    (safety population)	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-24.508335	11.89972	160.74573	85.74965	-41.621216
106	106	Adverse events  (any grade)  experienced by 15% or more of patients in either treatment group, and CTCAE grade 3 or higher events occurring in 3% or more of patients in either group	6	14	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-29.040808	16.390854	-57.059147	-61.697773	95.67917
107	107	MedDRA Summary of Treatment Emergent Adverse Events Occurring in >3% in Either Treatment Group by Primary System Organ Class and Preferred Term: All Subjects Population	6	15	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-21.486744	13.831818	-39.735306	-117.89273	36.001595
108	108	Safety endpoints and treatment-emergent adverse events of special interest, by treatment assignment over weeks 010  (study part 1)  and weeks 1020  (study part 2)	6	11	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-21.473368	15.612822	-42.395885	-151.24292	90.611824
109	109	Treatment-emergent adverse events possibly or probably related to treatment in at least 1% of patients  (intention-to-treat population)	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-25.165108	10.395507	-75.223915	-104.02365	40.975704
110	110	Treatment-emergent adverse events occurring in 10% or more of patients in either group during the double-blind period  (safety population)	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-20.90784	11.704739	-33.43642	-61.74926	51.602
111	111	Treatment-emergent adverse events in every treatment group during the 12-week treatment period  (safety population)	6	11	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-22.758022	12.848869	-11.665217	120.69797	107.71959
112	112	Grade 12 adverse events occurring in 10% or more of patients and all grade 35 adverse events in the fulvestrant plus palbociclib safety population  (all causalities and all cycles)	6	15	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-30.42213	13.267785	28.087809	-113.73861	136.01912
113	113	Treatment-emergent adverse events reported by 2% of patients in either treatment group during the double-blind maintenance period	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-21.629179	12.275166	-12.110555	-70.78907	66.681015
114	114	Overall Incidence of AEs, Discontinuations Due to AEs, and AEs Occurring in 2% of Patients During the Double-Blind Treatment Period  (Safety Population, n = 672)	6	10	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-19.630756	11.248892	-27.410706	-49.855736	29.970627
115	115	Recurrence-free survival, distant metastasis-free survival, and overall survival in the intention-to-treat population	6	6	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-17.219631	7.4892497	20.266533	-31.733803	65.00096
116	116	All serious adverse events, adverse events occurring in 10% or more of patients in any treatment group, and adverse events of special interest	6	10	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-25.819176	14.79918	-26.484365	-80.33704	114.67628
117	117	Most common adverse events leading to everolimus and exemestane discontinuation, dose adjustment, or dose interruption, with suspected relation to everolimus  (safety population, n=92)	6	15	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-25.703272	7.5819693	-59.463516	-29.446886	136.46233
118	118	Adverse events  *   of more than 2% difference between treatment groups  (for all grade adverse events)  and adverse events of CTC grade 3  (EFS population)	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-26.936459	15.245833	2.743127	-86.23605	130.2508
119	119	Serious adverse events and most common adverse events related or possibly related to treatment  (ITT population)	6	10	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-26.288727	11.705716	-137.17339	-77.26006	-83.46128
120	120	Treatment-related adverse events of any grade reported in at least 10% of patients and all grade 34 events in 78 patients who received nivolumab	6	11	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-29.286276	14.88415	-44.00022	-28.227907	84.42192
121	121	Treatment-emergent adverse events group in all participants who received 1 dose of study drug  (occurring in 5% in either treatment)	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-20.64537	9.400963	-53.2513	-119.2543	73.523735
122	122	Treatment-emergent adverse events, irrespective of association with study drug, by preferred term  *   and treatment  (safety set)	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-22.31138	9.120638	-20.450197	-126.10559	64.14651
123	123	Most common adverse events by treatment group, reported by 15% of patients at any grade or by 3% of patients at grade 3 severity  (safety population)   *	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-30.450489	14.923036	-67.82101	-39.997795	68.56709
124	124	Drug-related adverse events  (10% of patients in either treatment group with grade 12 and all grade 3 adverse events; NCI CTCAE 3.0)	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-28.13013	14.805868	-2.4725845	-159.66518	78.33685
125	125	Treatment-related select adverse events and treatment-related adverse events leading to discontinuation of both study drugs	6	13	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-26.019478	12.569645	3.9675646	-142.98471	110.44266
126	126	Summary of total adverse events and treatment-related adverse events through week 96 in the safety maintenance population	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-26.92856	11.544913	17.795362	-77.76881	94.88107
127	127	Grade 3 or 4 and serious adverse events and reactions, and adverse events leading to quinacrine discontinuation or dose reduction	6	11	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-28.77228	12.1355095	-28.869259	-43.451965	126.73858
128	128	Overall survival in all randomly allocated patients who received at least one dose of study treatment in the intention-to-treat population	6	8	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-18.064632	8.134286	-0.4818463	-31.309786	47.776688
129	129	Adverse events reported by 10% or more patients for grades 1 and 2 and all adverse events for grades 35  (safety population)	6	10	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-29.441854	13.692822	88.109085	-52.96392	-142.98737
130	130	Adverse events of 10% incidence in either treatment group or grade 3, 4 adverse events of 05% incidence in either treatment group  (safety set)	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-24.489944	15.33626	-4.8374634	-107.74614	98.5937
131	131	Drug-related adverse events  (10% of patients in either treatment group with grade 12 and all grade 3 adverse events) .	6	11	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-27.98305	14.47362	98.234505	113.98738	88.843765
132	132	Grade 3 and 4 adverse events  *   experienced by 2% or more of patients and adverse events leading to treatment discontinuation, after randomisation to rituximab maintenance or observation	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-28.192528	12.910984	-16.724594	-49.920605	97.48475
133	133	Common adverse events  (10% in either treatment group)  reported up to 28 days after study drug discontinuation  (safety population)	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-23.048763	10.430488	151.16594	64.53972	2.7092843
134	134	Treatment-emergent adverse events  (MedDRA HLT or PT)  occurring in 5% or more of patients in the placebo or combined dupilumab doses groups  *	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-20.174118	13.099814	-47.50016	-88.64067	63.29764
135	135	Overview of incidence of treatment-emergent adverse events by treatment at adverse event onset by system organ class	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-24.62913	13.207369	-39.527584	-113.82648	109.86447
136	136	Overall incidence of treatment-emergent adverse events occurring in 10% or more of patients who received one or more doses of study drug	6	12	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-20.029974	9.165945	92.04452	131.41872	-105.190765
137	137	Overview of adverse events, classified by Common Terminology Criteria for Adverse Events  (version 3.0)  in all patients who received at least one dose of study drug	6	13	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-24.691475	17.682697	-17.923548	-38.577984	163.80186
138	138	Incidence of grade 35 adverse events occurring in 2% or more of patients given chemotherapy with or without bevacizumab after disease progression following first-line bevacizumab-based treatment  (safety population  *  )	6	13	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-30.011292	9.895493	-67.79944	-64.521164	36.227413
139	139	Treatment-emergent adverse events leading to discontinuation of treatment  (intention-to-treat population)	6	10	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-24.363089	10.457536	41.066574	-43.724243	-149.2119
140	140	Virological response over time  (RVR and SVR12) , and on-treatment failure and relapse, according to treatment group in the intention-to-treat population	6	9	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-17.724724	10.485872	12.910635	-90.08969	7.7581263
141	141	Most common  (10%)  treatment-emergent adverse events by study group and preferred term  (safety population)	6	11	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-22.31042	9.96446	137.85402	91.08678	-4.6764817
142	142	Overview of treatment-emergent adverse events  (MedDRA preferred terms)  and injection-site reactions  (MeDRA high-level terms)  in the safety population	6	14	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-22.298296	7.391528	3.0044787	-103.58181	46.425518
143	143	Treatment-emergent adverse events leading to discontinuation of study drug in the safety population  (n=2485)	6	10	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-23.509502	9.923717	9.342818	-45.284393	118.892365
144	144	Patients with any adverse event and with grade 34 adverse events related to study treatment  (2-weekly regimen)	6	11	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-27.111967	13.476969	18.096422	-137.6878	70.62929
145	145	Incidence of prespecified treatment-emergent adverse events  (preferred terms)  during the double-blind period  (safety population, n=515)	6	13	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-21.157463	10.8158455	-21.826189	-82.65681	33.375397
146	146	Serious adverse events in any treatment group and treatment-emergent adverse events occurring in 5% or more of patients	6	10	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-24.501823	13.923093	-32.228672	-91.05043	88.27488
147	147	Treatment-emergent adverse events of any grade reported in at least 10% of patients in either group in the safety population	6	10	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-22.847206	11.61001	42.40546	86.779625	82.26472
148	148	Proportion of participants experiencing at least one grade 35 adverse event by 52 weeks that was possibly, probably, or definitely related to study treatment using a modified intention-to-treat analysis for a model based on the raw dataset and imputed dataset	6	13	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-27.00402	9.3539295	32.66818	-17.991743	138.1628
149	149	Treatment-related adverse events occurring in 5% of patients in either group from start of treatment to 30 days after end of treatment  (safety population)   *	6	13	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-23.073895	13.914551	-82.07768	-95.31903	81.88154
150	150	Early Clopidogrel and Glycoprotein IIb/IIIa Inhibitor Use in Patients Managed With Early Invasive Strategy  (Cath 48 h From Admission)  Versus Conservative Care  (Cath >48 h After Admission or No Cath)	7	14	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-1.956988	-12.557741	-58.659092	-27.56949	-5.3935885
151	151	Patients With Standardized Criteria for Urgent and Elective Coronary Angiogram, and Rates of Urgent PTCA and CABG Among These Patients During the 28 Days Following Onset of Unstable Angina, by Type of Hospital	7	18	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-3.624607	-6.806093	-154.94972	62.98452	72.62181
152	152	Procedures, Complications and Clinical Outcomes of Patients at Hospital Discharge in Invasive and Conservative Therapy Groups Following Matching by Propensity Analysis	7	14	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-0.02212783	-11.170182	-62.316483	57.23339	-2.9421356
153	153	A Summary of Time Frames of PTCA, Surgery, Antiplatelet Therapy and Complications in Patients Who Experienced Major Complications After Noncardiac Surgery Preceded by Intracoronary Stent Placement legend	7	14	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-1.8378034	-7.781267	-144.40042	19.805029	40.19138
154	154	Effect of Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle on Cardiac Electrophysiologic Parameters in Postinfarction Dogs legend	7	9	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	8.173837	-6.2960534	161.79013	36.03386	-34.203888
155	155	Plasma Renin Activities in Postinfarction Dogs Administered Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle legend	7	7	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	7.991366	-6.0208135	32.422188	36.198986	-75.51552
156	156	Effect of Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle on the Incidence of Lethal Ischemic Arrhythmias Developing in Response to Secondary Acute Posterolateral Myocardial Ischemia in Postinfarction Dogs	7	15	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	7.9585066	-7.4027023	12.576721	20.99649	-96.52471
157	157	Initial Procedural Outcome  (Among 608 CABG and PTCA Patients With IR Intended and 579 PTCA Patients With CR Intended if Randomized to PTCA Who Received Their Assigned Treatment)  legend	7	16	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-3.8647473	-11.624153	-104.55032	-14.466545	80.98521
158	158	Ischemic and Bleeding Outcomes 12 to 30 Months After Coronary Stent Treatment in all Randomized Patients, Stratified by Presentation With Versus Without Acute Myocardial Infarction	7	15	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	5.022937	-13.00042	4.861637	80.46984	95.91874
159	159	Death, MI, or Refractory Ischemia or Major Bleeding in Patients Undergoing PCI by Loading Dose of Clopidogrel or Type of GP IIb/IIIa Inhibitor	7	12	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-5.771374	-2.8904219	-35.18372	-46.5638	-38.31074
160	160	Procedures, Complications and Clinical Outcomes of Patients at Hospital Discharge in Invasive and Conservative Therapy Groups *	7	11	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	0.020677797	-10.99022	-43.433575	49.456886	3.8551614
161	161	Effect of Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle on Sinus Heart Rate, Mean Arterial Pressure and Electrocardiographic Intervals in Postinfarction Dogs legend	7	8	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	8.8491335	-6.2883306	9.212992	54.483276	-83.74005
162	162	Intraoperative and Postoperative Complications for Patients Undergoing Off-Pump and On-Pump CABG Surgery in New York State, 19972000	7	11	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-0.65698373	-6.712847	-167.89	-14.26144	24.236244
163	163	Risk of THV Thrombosis in Relation to Post-TAVR Antithrombotic Therapy Until 1- to 3-Month Post-TAVR Follow-Up  (Routine Follow-Up Visit 1)	3	7	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-2.4778392	-2.888408	37.38877	-11.962232	182.41609
164	164	Death, MI, Refractory Ischemia, Major Bleeding, and Net Clinical Outcome at 30 Days in Those Treated With a GP IIb/IIIa Inhibitor	7	10	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-5.6599603	-2.838925	-24.70516	-28.941689	-47.271442
165	165	In-Hospital Course of Patients With Acute Myocardial Infarction and Cardiogenic Shock Treated With or Without Intraaortic Balloon Counterpulsation	7	11	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	3.3229291	-9.890423	-46.608166	60.310684	43.59511
166	166	Sensitivity analysis and 1-year mortality in all patients and in patients who survived until day 14, day 30, day 60, and day 90 after acute myocardial infarction  (AMI)	7	6	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	2.9487848	-8.415739	-47.609566	52.281864	78.677864
167	167	Mortality Over Time Among All Patients in PCI Studies Randomizing Patients to Standard Therapy or Standard Therapy Plus Abciximab With a 12-h Infusion After PCI  (Excludes Patients Not Randomized to a Common Intervention [EPISTENT PTCA/Abciximab Group])  legend	7	18	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	0.85100985	-13.192169	-74.89852	52.5524	105.48397
168	168	Community Hospital Complications of Patients With Acute Myocardial Infarction and Cardiogenic Shock Treated With or Without Intraaortic Balloon Counterpulsation	7	12	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	3.1937501	-10.052917	-62.044724	45.109272	41.949123
169	169	Neurological presentations of 424 patients with gluten sensitivity, who presented with neurological dysfunction and were seen in the gluten sensitivity/neurology clinic, in Sheffield, UK, from 1994 to 2009	7	14	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-5.522581	-8.566127	-21.16466	7.6928496	156.74998
170	170	Revascularization Procedures in Post-Lytic NQMI Patients Randomized to Invasive  (INV)  or Conservative  (CON)  Management Strategies legend	7	11	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	5.2870045	-6.2645507	-102.48308	-46.123844	95.32842
171	171	Early and Late Outcomes of Hospital Survivors of AMI and Cardiogenic Shock According To Myocardial Infarction Type	7	10	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	4.273357	-10.380496	-49.140297	18.077936	26.374868
172	172	In-Hospital Outcomes of Elderly Patients  (65 years old)  With or Without Previous Angina 48 Hours Before Acute Myocardial Infarction	7	10	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	3.2955024	-7.8630877	-34.295544	33.98275	61.664005
173	173	Clinical Outcomes at 30 Days According to Consistent Therapy on Enoxaparin Versus Switch From Enoxaparin to Bivalirudin	7	11	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-0.56705207	-8.836268	6.962428	17.01085	25.95848
174	174	Clinical Outcomes Stratified by Stent Type and Peri-Procedure Administration of Platelet Glycoprotein IIb/IIIa Inhibitors	7	11	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-2.2301698	-10.107738	-85.296	-57.096615	-48.92402
175	175	In-Hospital Bleeding Complications of Patients With ST Segment Elevation Myocardial Infarction According to Thrombolytic and Antithrombin Therapy	7	12	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	0.9724355	-9.171196	-20.734694	38.461494	26.605436
176	176	Comparison of Admitting Diagnosis and Initial Hospital Bed Assignments of 29,585 Patients With LBBB and Acute MI in the National Registry for Myocardial Infarction 2  (June 1, 1994March 31, 1998)  legend	7	15	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	6.601537	-10.435191	-97.50661	31.820002	67.0635
177	177	30-Day and Long-Term Reinfarction According to Degree of ST-Segment Resolution at 90 Min and 4 Hours After Initiation of Reperfusion Therapy	7	8	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-2.8786535	-1.489007	15.691856	-39.81344	-15.620578
178	178	Comparison of Treatments Received by 29,585 Patients With Acute MI and LBBB With and Without Chest Pain in the National Registry for Myocardial Infarction 2  (June 1, 1994March 31, 1998)  legend legend	7	16	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	6.678444	-10.46326	-109.0624	49.79046	62.36812
179	179	Clinical Outcomes at Day 9 in Patients Undergoing Early PCI  (Within 24 h of Randomization)	7	6	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	0.012133369	-5.400192	-21.337042	-73.7214	-124.58043
180	180	Serial Electrocardiographic Changes in Patients With Suspected Acute Myocardial Infarction Who Were Not Receive Randomized to Prehospital Versus In-Hospital Thrombolysis	7	10	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	4.4600224	-8.681277	-63.21924	16.157658	61.932064
181	181	Clinical Outcomes at 30 Days in Patients With ST Segment Elevation Myocardial Infarction According to Thrombolytic and Antithrombin Therapy	7	12	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	0.8223822	-9.069838	-5.6077123	44.365433	41.719524
182	182	Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With>12 Months Versus12Months of Clopidogrel After IndexPercutaneous Coronary Revascularization With BMS	7	10	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	1.8213387	-4.8479304	-3.052001	-8.7260065	87.224556
183	183	Protective Role of Angina 48 Hours Before Acute Myocardial Infarction in Adult and Elderly Patients: Adjusted Regression Model for In-Hospital Death and Congestive Heart Failure or Shock and Combined End Points  (in-hospital death, congestive heart failure or shock)   a	0	15	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	15.706685	6.9031124	-148.39412	13.815693	92.081276
184	184	Protective Role of Angina 48 Hours Before Acute Myocardial Infarction in Adult and Elderly Patients: Unadjusted Regression Model for In-Hospital Death and Congestive Heart Failure or Shock and Combined End Points  (in-hospital death, congestive heart failure or shock)	0	15	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	15.707198	6.905102	113.446785	-6.3256307	-146.54643
185	185	In-Hospital Clinical Outcomes of Patients Undergoing Isolated Tricuspid Valve Surgery From 2004 to 2013  (Unweighted)	7	10	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	0.54297453	-5.929781	-34.374767	15.926063	91.52125
186	186	Short-Term and Long-Term Major Adverse Clinical Events in PCI Patients	7	6	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-4.381438	-1.324014	23.687082	-51.64425	21.935123
187	187	Early and Systematic Versus Guided or Delayed PCI  (Stent Era and Balloon Era)  After Fibrinolysis for STEMI	7	5	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	2.283019	-3.505485	8.745503	5.3415146	-7.447194
188	188	Effect of Surgery on Exercise Parameters in Patients Undergoing Mitral Valve Replacement and Patients Undergoing Mitral Valve Repair legend	7	15	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	0.69429535	-6.7782254	-146.19125	-72.050674	-28.241343
189	189	Individual Event Rates  (Event/Month)  and Therapy Episodes  (Episode/Month)  of Patients Pre- and Post-CRT Implantation	7	7	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-5.58882	-6.6053	-7.7167516	-3.108589	122.18693
190	190	Complications of Thrombolytic Therapy of Prosthetic Valve Thrombosis in 107 Patients	7	6	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-1.1380326	-5.393056	71.97364	-26.250502	-25.92919
191	191	Clinical Outcomes in Surgically and Nonsurgically Treated Patients After Acute Myocardial Infarction	7	9	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	2.3601205	-7.899455	-53.792435	-111.920746	-66.3165
192	192	Effects of aspirin on bleeding episodes and related complications in elective-arthroplasty patients up to day 35	7	7	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-1.4772912	-4.8513455	-71.59981	3.9623864	98.18838
193	193	Hierarchical Incidence of MACE During Hospitalization and 12-Month Follow-Up in Patients With Successful Recanalization of a CTO	7	5	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-2.746191	-4.6721163	30.773588	-72.17405	54.492146
194	194	1-Year Clinical Outcomes in Patients With In-Hospital Versus Out-of-Hospital Definite/Probable Stent Thrombosis	7	10	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	2.1452408	-6.3102026	-25.639599	2.1491294	55.6675
195	195	30-Day and 1-Year Event Rates According to the Occurrence of Major VC Versus No Major VC Up to 30 Days	4	6	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-4.8751926	-0.11795874	32.75873	-21.722843	9.40208
196	196	In-Hospital Invasive Coronary Procedures, Medications, Complications and Mortality of Patients Treated or Not Treated by Acute Reperfusion legend	7	12	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	2.4161232	-11.362492	-83.9606	38.47167	22.450111
197	197	Ischemic and Bleeding Outcomes in all Randomized Patients, According to Acute Myocardial Infarction Status, From12 to 30 Months After Coronary Stent Treatment	7	13	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	5.0080338	-12.972478	-9.16823	70.297714	82.50582
198	198	Reported Cause of Death and Procedures Performed in Post-Lytic NQMI Patients Randomized to Invasive  (INV)  and Conservative  (CON)  Management Strategies legend	7	12	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	5.3704104	-6.2338767	-115.08095	-14.629352	46.48549
199	199	Study Endpoints in Matched Patients: Admission Rate, Length of Stay, MACE, Additional Patient Follow-Up, and Downstream Resource Utilization With CCTA Versus Standard Evaluation  (Both, n= 894)	7	15	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-3.7006059	-5.173137	-121.49745	43.053516	118.26955
200	200	5-year relative survival  (%)  by use of state-specific and race-specific life tables and age-standardised to ICSS weights  *   with 95% CIs     for adults  (aged 1599 years)  diagnosed with cancer of the breast  (women) , colon, rectum, or prostate during 199094 and followed up to Dec 31, 1999, by ra US populations	2	18	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	5.23209	24.685549	-124.25088	91.59796	105.120895
201	201	Decomposition analysis of the change of global disability-adjusted life years  (thousands)  by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age-specific, sex-specific, and cause-specific disability-adjusted-life-year rates	4	25	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-30.50427	-1.0752393	115.293465	-109.83545	25.390877
202	202	Global all-age attributable deaths and DALYs, in 2006 and 2016, and percentage change of deaths, age-standardised death rates, DALYs, and age-standardised DALY rates between 2006 and 2016, for all risk-outcome pairs, both sexes combined	4	17	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-1.3806324	18.1897	112.13017	-122.70276	-62.033825
203	203	40-year trends in the index of net survival for all cancers combined at 1, 5, and 10 years after diagnosis in adults  (1599 years)  in England from 1971 to 2011 and trends in the age-adjusted net survival for 21 selected cancers in England from 1971 to 2011 by sex	2	16	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	7.827913	21.741743	54.03414	-89.646774	24.08943
204	204	Age-standardised 5-year net survival  (%)  with 95% CI: adults  (1599 years)  diagnosed with one of eight common malignancies  (oesophagus, stomach, colon, rectum, liver, pancreas, lung, or melanoma of the skin)  by continent, country, and calendar period of diagnosis	2	22	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	3.6331487	22.972118	68.860664	-127.05523	-3.396017
205	205	40-year trends in the index of net survival for all cancers combined at 1, 5, and 10 years after diagnosis in adults  (1599 years)  in Wales from 1971 to 2011 and trends in the age-adjusted net survival for 21 selected cancers in Wales from 1971 to 2011 by sex	2	16	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	7.826757	21.74169	-93.88154	-131.32924	105.17873
206	206	5-year relative survival  (%) , age-standardised to ICSS weights  *   with 95% CIs for adults  (aged 1599 years)  diagnosed with cancer of the breast  (women) , colon, rectum, or prostate during 199094 and followed up to Dec 31, 1999: continent, country, and region	2	20	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	5.108365	24.546423	43.34798	-129.72408	23.34304
207	207	Age-adjusted annual incidence and mortality rates  (per 100000 person-years) , disability-adjusted life-years  (DALYs)  lost, prevalence  (per 100000 people) , and mortality-to-incidence ratio  (MIR)  by age groups in high-income and low-income and middle-income countries, and globally in 1990, 2005, and 2010	4	15	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	2.5719056	15.59716	118.49064	-56.390087	-15.356708
208	208	Observed  (obs)  number of sibling pairs with cancer and standardised incidence ratios  (SIR)  in siblings of children with cancer, followed-up in childhood and adolescence, stratified by type of cancer of index patient	2	19	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	-10.570611	-18.29371	111.65589	-75.93334	86.06544
209	209	Male dose-related excess mortality in ever-drinkers as a proportion of all mortality in male ever-drinkers and never-drinkers, by age and underlying cause of death	4	14	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	16.446783	20.902967	98.0753	-83.11019	135.11168
210	210	Female dose-related excess mortality in ever-drinkers as a proportion of all mortality in female ever-drinkers and never-drinkers, by age and underlying cause of death	4	14	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	16.451889	20.903412	-118.02358	38.580605	-69.41636
211	211	Top 10 causes of disability-adjusted life-years  (DALYs)  in males, females, and both for ages 1014 years, 1519 years, and 2024 years, 1990, 2005, and 2013	4	12	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	4.0433607	19.594769	91.37073	-76.21797	7.355325
212	212	Age-standardised and sex-standardised mortality ratios of all-cause, suicide-related, and cancer-related mortality in patients with chronic fatigue syndrome, compared with the general population in England and Wales in 2011	2	8	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	-13.625556	-2.7796512	105.291	-44.246075	46.28418
213	213	5-year age-standardised net survival for adults  (aged 1599 years)  diagnosed with one of ten common malignant diseases and children  (aged 014 years)  with ALL, by continent, country, and calendar period of diagnosis	2	18	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	3.3929563	22.885439	141.06032	27.383324	-91.98683
214	214	Global life expectancy at birth and at age 50, age-standardised death rates, age-standardised YLL rate, and total deaths, by sex, 19802015	4	11	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-0.7949121	15.814043	-138.61696	79.34898	-55.08502
215	215	Observed and expected deaths from breast cancer in the initial cohort within 16 years and rate ratios  (intervention centres vs combined comparison centres)  for cases diagnosed within 7 and 10 years of date of entry	2	14	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	8.8578415	17.899765	-118.817024	-137.38315	-13.879844
216	216	Life years lost and excess life years lost by cause of death in people with and without mental disorders	4	12	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	2.9937391	18.686085	83.6498	-70.23353	-25.494755
217	217	Adjusted hazard ratios  (HRs)  for mortality in relation to childhood BMI and BMI change during puberty for 37672 Swedish men followed for a mean of 378 years after age 20 years	4	9	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	4.6847014	15.926418	82.051506	-37.88566	10.324653
218	218	Standardised incidence ratios  (SIRs)  for nervous-system tumour types subdivided by age at diagnosis in offspring with a sibling diagnosed with any nervous-system tumour	2	14	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	-9.719049	-15.4269	65.59197	-92.34686	105.731255
219	219	Male relative risk of death at ages 1574 years, by proxy-reported alcohol intake  (other drinkers vs reference drinkers, excluding never-drinkers)  and certified cause  (other causes vs control diseases)	4	20	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	14.373529	22.802599	142.3068	-1.7212492	41.30975
220	220	Unadjusted and Adjusted Association of Heart Rate Variability Variables With All-Cause Mortality, Cardiac Mortality, Sudden Cardiac Mortality, Sudden Cardiac Autopsy-Verified Mortality, Sudden Cardiac Mortality for Both Genders, Nonsudden Cardiac Mortality and Nonsudden Cardiac Mortality With Cerebrovascular Mortality legend legend	0	28	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	6.9428725	-25.085682	125.79462	-20.815514	4.4055133
221	221	Observed  (O)  and expected  (E)  numbers of cancers, standardised incidence ratio  (SIR)  with 95% CI for colorectal cancer in first-degree relatives of patients with either ulcerative colitis or Crohn's disease in Sweden 195595	2	17	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	-8.959729	-17.482916	80.89778	-73.10406	57.071407
222	222	Global deaths, age-standardised death rates per 100000, YLL numbers, and age-standardised YLL rates per 100000, and percent change between 2006 and 2016 for both sexes combined for all GBD causes and levels 1 through 4 of the cause hierarchy	4	16	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-2.0384846	17.173822	76.473915	-130.94577	-56.119644
223	223	Observed  (obs)  and expected  (exp)  numbers and standardised incidence ratios  (SIRs)  for all cancers in 42277 siblings of children with cancer, stratified by age at diagnosis	2	13	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	-9.742683	-17.451506	83.38967	-84.27497	80.083115
224	224	Female relative risk of death at ages 1574 years, by proxy-reported alcohol intake  (other drinkers vs reference drinkers, excluding never-drinkers)  and certified cause  (other causes vs control diseases)	4	20	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	14.372598	22.804659	-108.64166	-39.438423	-7.9209714
225	225	Observed  (obs)  number of sibling pairs with cancer and standardised incidence ratios  (SIR)  in siblings of children with cancer, followed-up in adulthood, stratified by type of cancer of index patient	2	18	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	-10.511739	-18.236698	-131.41359	32.8876	-122.67695
226	226	Incidence rates  (per 100 person-years)  and HRs for all incident cancers, lung cancers, and non-lung cancers	2	10	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	0.47124314	8.611554	82.22386	-116.899254	58.871998
227	227	Top ten causes of years lost due to disability  (YLDs)  in males, females, and both for ages 1014 years, 1519 years, and 2024 years, 1990, 2005, and 2013	4	11	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	3.9862645	19.579563	93.39166	-91.83047	-7.448959
228	228	Age-adjusted rates for all-cause, cardiovascular disease, and ischaemic heart disease mortality by sex-specific ascorbic acid quintile in men and women	4	12	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	7.980389	-23.634352	148.6722	-55.524654	27.402279
229	229	Death rates  (per 1000 person years) , number of deaths, and mortality ratios for various causes of death among men aged 4455 years, according to diabetic  (NIDDM)  and non-diabetic  (non-DM)  status in the Whitehall, Paris Prospective, and Helsinki Policemen studies	4	19	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-3.944945	16.352898	111.547966	-69.62935	-56.917973
230	230	Decomposition analysis of the change of global years lived with disability  (thousands)  by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age-specific, sex-specific, and cause-specific years lived with disability rates	4	24	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-30.534447	-1.2604758	5.039629	-129.62447	-98.43116
231	231	Age-standardised 5-year net survival  (%)  with 95% CI: adults  (1599 years)  diagnosed with one of seven common malignancies  (breast, cervix, ovary, prostate, brain, myeloid, and lymphoid)  and children  (014 years)  diagnosed with one of three common malignancies  (brain, acute lymphoblastic leukaemia, and lymphoma)  by continent, country, and calendar period of diagnosis	2	30	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	2.4445658	23.140268	39.75819	-136.39545	-16.967594
232	232	Decomposition analysis of the change of DALY numbers  (thousands)  by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age-specific, sex-specific, and cause-specific DALY rates for the Arab world	4	22	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-30.6363	-1.8855621	138.45491	-101.571465	42.755478
233	233	Unadjusted breast-cancer incidence and mortality from incident tumours, with unadjusted and adjusted relative risks of breast-cancer death	2	12	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	0.4731791	9.822815	104.397285	-128.03813	82.26424
234	234	Relative risks  (95% CIs)  of death from all causes, cardiovascular disease  (CVD) , coronary heart disease  (CHD) , stroke, and external causes by typical dose per occasion in men who drink at least once a month	4	14	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	11.635163	-22.994602	173.73546	-3.2842336	-54.382633
235	235	Substance use disorders as predictors of all-cause mortality, suicide, and deaths from accidents in people with schizophrenia, bipolar disorder, or depression	4	10	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	0.43048602	12.263485	152.08955	-30.371042	-28.348938
236	236	Observed and expected deaths from breast cancer  (diagnosed in all years)  in the initial cohort within 16 years, andrate ratios  (intervention centres vs combined comparison centres)	2	15	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	8.84914	17.901815	130.04617	129.2055	31.542238
237	237	Age-standardised death rates, YLLs, and YLDs, and life expectancy at birth and HALE at birth for 1990 and 2010 for both sexes combined	4	12	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-0.8931528	15.1378145	71.3049	-113.36779	-100.10322
238	238	Deaths  (in thousands)  and age-standardised death rates per 100000 for 231 causes in 1990 and 2010 for all ages, both sexes combined, and percentage change from 1990 to 2010 in China	4	12	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-2.2678819	16.337387	85.72653	-101.4443	-60.76997
239	239	Cardiovascular disease mortality according to overweight at age 8 years  (childhood)  or at age 20 years  (young adult age) , or both	4	8	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	4.836827	16.417162	60.449474	-50.002285	4.358093
240	240	Crude and adjusted hazard ratios  (95% CI)  for death from any cause, death due to IHD, and admission for or death from IHD related to absolute values of birthweight	0	5	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	-4.759542	18.520033	-137.72688	-65.393555	65.15408
241	241	Comparison of time trends in premature mortality before and during the 2008 economic crisis, by cause of death  (ICD-10)   *   and socioeconomic groups     and household car ownership, in the 2001 Spanish Census Cohort of people aged 1074 years	4	10	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-2.9508247	13.616006	163.93234	-79.57381	-19.410927
242	242	Relative risks  (95% Cis)  of death from all causes, cardiovascular diseases, and coronary heart disease, by frequency of drinking, stratified by typical dose per drinking occasion-drinkers only	4	15	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	11.659639	-23.00288	-169.5926	-27.550165	66.69181
243	243	Relative Rates  (95% CI)  of CVD Mortality, Incident CHD, and Total Mortality in Gender-Specific Quintiles of the Heart Rate-Adjusted QT	4	8	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	7.584315	-23.982939	128.33568	-45.04585	20.061768
244	244	Standardised incidence rates for endometrial and breast cancer per 1000 women over a 5-year period in current users and never users of HRT at recruitment	2	13	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	-1.0809819	8.538001	79.570305	-152.62889	41.226124
245	245	Exposure rates and odds ratios for wheeze and skin sensitivity to D pteronyssinus adjusted for age, sex, and urban or rural residence	4	6	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	0.9777761	6.930885	83.27919	-31.75515	-64.545425
246	246	Global deaths, disability-adjusted life-years, and age-standardised rates attributable to ambient particulate matter pollution in 2015	4	12	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	0.2970181	16.389715	53.214935	-89.89698	-24.694414
247	247	Global deaths for 235 causes in 1990 and 2013 for all ages and both sexes combined and age-standardised death rates	4	9	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-2.004163	16.21757	-82.622055	21.948166	134.35199
248	248	Adjusted incidence rates, hazard ratios, and 95% CIs for cigarette smoking and lung cancer by sex	2	8	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	0.414061	7.9917164	-31.53907	36.604687	181.24493
249	249	Crude and adjusted hazard ratios  (95% CI)  for death from any cause, death due to IHD, and admission for or death from IHD in relation to combinations of adverse obstetric outcomes	4	7	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-4.7591076	18.529028	105.8465	-32.768185	-103.54805
250	250	Diagnostic performance of Xpert MTB/RIF assay compared with smear microscopy, Lwenstein-Jensen medium, and Bactec MGIT960 system	5	12	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	-19.157627	-9.749778	-17.710825	-78.42503	-181.70724
251	251	Subset Intravascular Ultrasound Analyses of Changes in the Cross-sectional Area of Lumen External Elastic Membrane and Plaque+Media  legend	3	12	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	24.792934	2.3557775	-93.80476	-16.242626	-40.447838
252	252	Diagnostic accuracy of PECARN, CATCH, and CHALICE clinical decision rules when analysed using rule-specific inclusion criteria, exclusion criteria, predictor variables, and outcome measures	7	15	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	19.438646	5.0099792	-131.76126	-58.47355	20.157879
253	253	Diagnostic performance of Xpert MTB/RIF assay compared with the combined reference standard  (smear microscopy, Lwenstein-Jensen medium, and Bactec MGIT960 system)	5	12	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	-19.168201	-9.927768	12.8752985	156.51999	89.45064
254	254	Per-protocol relative sensitivity and PPV of HPV versus Pap for a CIN2 or worse endpoint in different age groups with different cutoffs of HPV tests	6	4	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	12.9390135	13.132734	7.321357	89.56853	50.877323
255	255	values on agreement of goitre diagnosis between examiners A, B, and C, between different classification systems in morning sessions, and between morning and afternoon sessions with the same classification system	1	8	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	14.689717	3.0874538	87.25557	168.24118	-13.294296
256	256	Axial Distribution of the Changes in Lumen, External Elastic Membrane and Plaque Plus Media Cross-Sectional Areas  (according to individual slices)	3	16	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	24.61601	2.2462192	-100.05029	-9.60154	-60.35009
257	257	Proportion of participants reporting at least one severe rotavirus gastroenteritis  (RVGE)  episodes  (per protocol clinical definition)  and vaccine efficacy against severe RVGE during three efficacy periods  (according-to-protocol cohorts for the 2-years' efficacy subset)	4	23	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-3.8761694	-19.909994	4.118466	-137.07011	-52.27797
258	258	Performance of smear microscopy, clinic-based nurse-administered Xpert MTB/RIF, and laboratory-based technician-administered Xpert MTB/RIF, per treatment site and overall	5	8	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	-19.183716	-8.272621	-41.08449	50.900448	139.08029
259	259	Inclusion and exclusion criteria, predictor variables, and outcome measures of PECARN, CATCH, and CHALICE clinical decision rules  8,9,12	7	12	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	19.423218	5.005498	165.14217	80.29003	45.117912
260	260	Efficacy of RIX4414 against severe rotavirus gastroenteritis and severe gastroenteritis during the 2-years' efficacy period  (ATP cohort for the 2-years' efficacy subset)	4	13	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-2.678415	-19.779074	-24.344866	-121.01991	-42.610832
261	261	Epinephrine-Induced Changes in the max QTc-e, the min QTc-e, the QTc-eD, the max QTc-p, the min QTc-p, and the QTc-pD, Which Are Obtained From all 87-Leads, in the LQT1, LQT2, and Control Patients legend	5	8	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	0.23279892	-3.8334434	-66.30542	29.860435	-34.31312
262	262	Effect of Using Different Cutoff Values for BNP on Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value, and Accuracy in Predicting Death  (All-Cause Including the Cardiac Death)  in Referred and Not-Referred Groups	0	19	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	18.312	13.547791	77.76559	148.43292	54.201393
263	263	Findings for all 441 women who were negative on initial colposcopy and were called back for a second colposcopy, including four-quadrant cervical biopsies and endocervical curettage, because of unsatisfactory or ASC-H+ cytology, positive careHPV  (RLU/cut-off ratio cut-point of 05) , or positive HC2 findings	0	12	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	-5.8369346	-13.386232	23.996061	127.90823	137.08972
264	264	Determining Central SBP Cutoff Values Based on the Sensitivity and Specificity Associated With Cuff SBP Cutoff Values for Predicting Cardiovascular Mortality	0	10	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	16.574097	14.404855	30.891964	122.355995	32.226326
265	265	Vaccine efficacy against any and severe rotavirus gastroenteritis according to detected rotavirus G types  (according-to-protocol cohort)	4	10	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-1.6259012	-18.474276	-74.72967	-118.61457	-28.68618
266	266	False-positive recall proportion shown according to double-reading protocols, and comparison of false-positive recall for screening integrating 3D mammography vs standard 2D mammography alone	0	15	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	-3.1930404	10.224801	-70.57245	143.67227	79.74966
267	267	Comparisons of Area Under the ROC Curve Along With LR+ and LR for BNP or NT-proBNP Assays to Diagnose or Exclude Acute HF in Various Large Trials of Acute Dyspnea	7	10	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	3.996419	-4.4704328	-72.61499	8.36328	-7.021589
268	268	Sensitivity, Specificity, Positive Prognostic Value and Negative Prognostic Value of the Ability to Exercise to Bruce Stage 3 and a Duke Score 6	0	11	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	16.834356	11.626257	32.379536	163.2338	42.846638
269	269	Vaccine efficacy against any and severe rotavirus gastroenteritis, admission, and medical attention  (according-to-protocol cohort)	4	11	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-1.9910649	-17.971863	-76.189606	-93.87818	-29.762722
270	270	The Number of Patients With True-Positive, False-Negative, True-Negative, and False-Positive Test Results	0	10	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	-3.7548265	8.693246	-50.01181	112.26852	75.36413
271	271	Vaccine efficacy against cervical intraepithelial neoplasia grade 2 or more  (CIN2+) , or grade 3 or more  (CIN3+) , colposcopy referrals, and cervical excision procedures associated with human papillomavirus  (HPV) -16/18, five non-vaccine oncogenic types, and irrespective of HPV DNA in lesion	6	13	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-1.0569863	-15.66212	-91.78573	-142.42047	-70.56922
272	272	Relative sensitivity and specificity for CIN2+ and sensitivity for CIN3+ under different screening policies based on 220 CIN2 and 233 CIN3+ histologies detected in 18386 women in the revealed group in round 1	0	6	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	13.76665	13.569652	-3.794018	116.04282	56.738705
273	273	Individual Components of Secondary Efficacy Endpoint of Persistent WRF	6	2	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	0.43088782	-1.3809432	-57.041588	42.735424	-69.225426
274	274	Sensitivities, specificities, positive and negative predictive values, and probabilities for comparison of differences in sensitivities	0	10	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	15.289536	12.554981	-155.04782	-3.756678	-18.745272
275	275	One-Year Outcomes for the Lean, Overweight, and Obese Categories Stratified by Median BNP  (452 pg/ml)	7	4	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	0.82303494	-2.4620774	-2.6114686	110.719315	-78.113365
276	276	Sensitivity, specificity, positive predictive values, and negative predictive values, by CSF -synuclein cutoff value	0	11	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	16.968357	13.316782	53.45917	136.68929	40.149887
277	277	Comparison of acid-fast-bacilli smear-positive, smear-negative, and smear-indeterminate patients	5	5	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	-8.000324	-0.6452485	-69.41758	108.00996	119.47349
278	278	Diagnostic sensitivities  (SE) , specificities  (SP) , false-negative  (FN)  and false-positive  (FP)  cases in each conventional BIT subtest and in combinations of two and three subtests  (n=52)	0	10	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	14.086283	10.901185	-55.789597	125.93358	52.70054
279	279	Proportion of participants reporting severe rotavirus gastroenteritis  (RVGE)  episodes with a score of 11, 19 and 20 on the Vesikari scale and efficacy of vaccine during the 2-years' efficacy period  (according-to-protocol cohort for efficacy)	4	19	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-3.6423597	-19.662954	177.99255	18.598297	10.405195
280	280	Pooled estimates of associations of TP53 codon 72 genotype and cervical histology of 33 studies; and invasive cervical cancer cases of 25 studies in subgroups of HPV status, ethnic group, and different quality criteria	3	11	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-11.944925	5.3686523	-24.463486	169.40746	57.677303
281	281	Interim Operative Procedures Performed in 38 Stage I Operative Survivors Before Stage II Operation	7	7	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-11.037802	0.03338937	-141.42453	-34.13353	-66.53402
282	282	Subgroup Analyses for Death, Major Amputation, Likelihood of Any Revascularization, and Likelihood of Endovascular Revascularization in the Study Cohort on the Basis of A PrioriDefined Subgroups	3	7	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	2.223776	3.465799	41.70395	-156.3898	-97.48711
283	283	Summary of Studies That Used Measured EOAi to Assess VP-PM: Data of Moderate and Severe VP-PM Analyzed Separately	3	10	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-2.3456922	5.8284106	10.067252	24.5353	-49.689922
284	284	Ratio of Actual THV Stent Area Measured With CT to Nominal THV Area According to THV Size and Degree of Underfilling	2	5	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	3.1214275	-1.0383509	-22.273853	-20.17021	-12.932242
285	285	Patients with a positive smear microscopy, Xpert MTB/RIF, or culture result, and days to result, per allocation group	5	8	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	-6.8212123	-0.8587449	-43.52554	88.63495	113.19616
286	286	Hazard Ratios for Different Endpoints per 1 SD Increase of ST2 Level or NT-proBNP Level  (on the Log2 Scale)  at Any Point in Time Using Repeated ST2 and Repeated NT-proBNP Measurements in a Joint Model	0	6	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	3.0601482	5.5572047	43.940495	19.324495	1.98675
287	287	Stent thromboses according to ARC criteria for definite stent thrombosis and according to per-protocol definitions used in individual trials	4	7	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	2.3871574	-2.2090104	-19.352724	-10.171784	20.645706
288	288	Sensitivity, specificity, and positive and negative predictive value for retinopathy at different fasting plasma glucose cutoffs	0	11	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	15.515152	12.741831	-145.99945	-25.597818	-18.354053
289	289	Lumen Area, Vessel Area and Plaque Area of Cross Sections Arranged in the Six Sections  legend	3	9	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	25.901348	3.0097878	-66.260956	-14.254244	-42.133854
290	290	Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value of Various Cut-Off Values for the Indicated Parameters	0	11	regress(33),model(31),hazard(24),ventricular(23),multivari(23),analysi(23),proport(21),death(21),valu(21),mortal(20)	17.075983	13.054439	48.165966	136.1483	62.79405
291	291	Effect of the 9vHPV vaccine on the incidence of persistent infection, cervical disease, cervical cytological abnormalities, and cervical definitive therapy related to each HPV type in the per-protocol efficacy population	4	12	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-3.4031587	-15.433477	-64.85494	-163.68443	-38.41993
292	292	APOE genotypes of AD patients and aged non-AD patients positive or negative for HSV1 in brain  (frontal lobe and temporal lobe)	2	8	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	-2.1288483	-6.2815995	-84.500305	87.40082	79.34028
293	293	Efficacy against CIN2+ and CIN1+ associated with HPV16 or HPV18 in the total vaccinated cohort for efficacy	4	5	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-1.886637	-16.110952	81.41937	7.0170374	-89.77128
294	294	Vaccine efficacy against all-cause severe gastroenteritis and admission  (according-to-protocol cohort for efficacy)	4	10	year(36),death(34),caus(33),efficaci(19),rat(19),specif(17),mortal(16),adjust(16),relat(16),chang(13)	-2.2405956	-17.645615	-52.75532	-97.709274	-30.886703
295	295	Key Eligibility Criteria and Key Exclusion Criteria	7	4	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	1.4699984	-0.96562827	35.840458	55.161625	-119.76549
296	296	Value of the Aortic Effective Regurgitant Orifice Area Calculated With the Proximal Isovelocity Surface Area Method and Quantitative Doppler and Two-Dimensional Echocardiographic Methods in the Overall Study Group and in Subgroups of Patients	3	13	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-14.487375	5.5494328	-140.46529	-114.09436	-54.522163
297	297	Percentage of Total Cross Section Represented by Plaque Area  (Difference Between Lumen Area and Area Delimited by Internal Elastic Lamina)  at Either 7 or 21 Days After Treatment with rhVEGF  (2 g/kg by a Single Intramuscular Injection)  or Albumin legend	3	12	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	26.421835	3.3166783	-65.33584	-24.417757	-64.738106
298	298	Summary of Studies That Use Measured EOAi to Assess VP-PM: Data of Moderate and Severe VP-PM Are Combined	3	8	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-2.295741	5.7728996	15.621101	33.17521	167.41891
299	299	Comparison of ARIC JUPITER-Eligible Group, JUPITER Placebo Arm, and JUPITER Treated Arm: Event Rates	6	7	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-10.770591	8.84065	-152.46768	-99.086685	33.954357
300	300	Per Vessel Territory Diagnostic Accuracy of Coronary Computed Tomography Angiography, Transluminal Attenuation Gradient, Contrast Opacification Difference  (Maximum, Mean, and Minimum) , and Quantitative Coronary Angiography Compared With Fractional Flow Reserve  (N = 78)	5	23	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	14.616059	-15.905762	-54.15638	151.5605	-29.910997
301	301	Basal and  () Isoprenaline-Stimulated cAMP-levels of CHW-beta1 Cells in the Presence of Rabbit  (70 nmol/liter) , Mouse  (7 nmol/liter) , or Human Anti-beta1-ECII  (2 mol/liter)	6	19	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-5.7072797	25.47374	-123.67339	-26.462536	-124.09052
302	302	Basal and  () Isoprenaline-Stimulated cAMP-levels of CHW-beta1 Cells in the Presence of Rabbit  (70 nmol/liter) , Mouse  (7 nmol/liter) , or Human Anti-beta1-ECII  (2 mol/liter)	6	19	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-5.7072797	25.47374	-123.67339	-26.462536	-124.09052
303	303	Comparison of MR, Doppler Echocardiography and Catheterization-Derived Peak Pulmonary Vein Blood Flow Gradients  (mm Hg)  in Patients With Pulmonary Venous Pathway Obstruction	5	15	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	-8.931875	13.724126	-112.172295	-114.927925	25.547758
304	304	Individual Peak Myocardial Videointensity Data  (in gray scale units)  in Middle and Lateral Segments of Original Stenosis Zone and Adjacent Perfusion Bed in the Presence of One- and Two-Vessel Stenosis During Both Rest and Dobutamine Stress Echocardiography	5	13	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	16.225983	0.61377555	-94.68518	62.030754	-94.37426
305	305	Peak Tissue Doppler Velocity at Rest and During Dobutamine Stimulation Related to Results of 18F-Fluorodeoxyglucose Positron Emission Tomography for 192 Dyssynergic Segments at Rest	5	14	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	19.067167	0.4269376	97.38436	-162.52025	-12.276896
306	306	Comparison of Magnetic Resonance Imaging Findings Based on Dobutamine-Induced Systolic Wall Thickening and End-Diastolic Wall Thickness With Postrevascularization Recovery of Systolic Wall Thickening	5	18	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	17.028967	-3.196451	-109.61256	120.542076	-53.922226
307	307	Coronary Flow Velocity Change in Coronary Aneurysms at Rest and Coronary Flow Reserve in 25 Patients With Kawasaki Disease and Aneurysmal Lesions in 29 Coronary Vessels  (group 2)	5	18	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	9.556099	-13.982416	-140.02336	64.95312	22.98689
308	308	Peak Systolic SR Data at Rest and During Dobutamine Stimulation Related to Results of 18F-Fluorodeoxyglucose Positron Emission Tomography for 192 Dyssynergic Segments at Rest	5	13	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	19.01356	0.42700857	-72.58978	84.198364	-112.42742
309	309	Forearm Blood Flow During Brachial Artery Infusion of Saline, l-Arginine Alone, Nitroprusside, Acetylcholine and Acetylcholine Plus l-Arginine in Control Subjects and Hypertriglyceridemic Patients	5	16	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	-3.5837488	-8.75068	-181.72246	33.1139	5.2039466
310	310	Coronary Flow Velocity Dynamics in Eight Patients With Kawasaki Disease and Ischemic Findings on Exercise Stress Testing and Normal Coronary Arteries on Angiography  (group 4)	5	17	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	10.110904	-13.2544	-119.44522	77.81944	12.110117
311	311	Variable Inter-Compression Analysis Between the Repeated Measurements  (t1)  of 48 Coronary Obstructions in the Original and the Compressed/Decompressed  (CR 6, 10 and 16)  Image Series and the First Measurements  (t0)  in the Original Image Series legend	7	17	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	24.262249	9.357527	-5.1565623	165.4239	-65.11577
312	312	Variable Inter-Compression Analysis Between the Repeated Measurements  (t1)  of 48 Coronary Obstructions in the Original and the Compressed/Decompressed  (CR 6, 10 and 16)  Image Series and the First Measurements  (t0)  in the Original Image Series legend	7	17	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	24.262249	9.357527	-5.1565623	165.4239	-65.11577
313	313	Peak Pulmonary Vein Blood Flow Velocity  (cm/s)  of Patients With Pulmonary Venous Pathway Obstruction from MR Velocity Mapping and Doppler Echocardiography legend legend	5	16	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	-8.86133	13.667571	-114.96391	7.1076217	-0.3931325
314	314	Sensitivity of Dipyridamole, Dobutamine Stress Echo and Myocardial Perfusion Scintigraphy for the Detection of Isolated Left Anterior Descending Coronary Artery Disease With and Without Multivessel Disease legend	5	15	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	9.885445	-10.746832	-98.88617	114.292534	-95.7778
315	315	Per-Vessel Territory Diagnostic Accuracy of QCA, Coronary CTA, Combined CTA+ CTP, Combined CTA+ TAG320, and MDCT-IP Assessments, Compared With FFR	5	10	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	10.798428	-4.550088	-32.397755	91.1099	-16.9
316	316	Value of Response to Dobutamine at the First Week  (Wall Thickening With Dobutamine >2 mm)  for Predicting Normal Segmental Wall Motion at the Sixth Month  (Wall Thickening >2 mm)  Depending on the Transmural Extent of Necrosis	5	14	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	17.730124	-3.2121227	158.85126	-64.37982	-69.75921
317	317	Diagnostic Performance of Multislice Spiral Computed Tomography Coronary Angiography for the Detection of Significant Obstructive Lesions	5	12	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	14.491388	-12.098351	-64.63765	111.906105	-38.95962
318	318	Contractile Responses to Potassium  (K+125 mmol/liter)  Phenylephrine  (PE, 1 mol/liter)  and Angiotensin II  (1 and 100 nmol/liter) , and Dilator Responses to Acetylcholine  (10 mol/liter)  in Human Internal Mammary Artery Segments From Patients With the DD or the II/ID Genotype legend	6	14	event(78),advers(70),treatment(66),grade(30),group(29),popul(28),patient(26),safeti(22),emerg(22),relat(17)	-6.791223	25.916847	-106.045074	-41.041412	-102.606964
319	319	Comparison of Thallium-201 and Technetium-99m Tetrofosmin Single-Photon Emission Computed Tomographic Dipyridamole Imaging Data in 364 Scan Segments	5	13	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	15.340525	-8.822446	-68.90569	157.0403	-76.95568
320	320	Diagnostic Accuracy of Two-Dimensional Dobutamine Stress Echocardiography, TDI and SRI for Detection of Viability Determined by 18F-Flurodeoxyglucose Positron Emission Tomography	5	11	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	12.4110155	-5.6665025	-51.87483	85.68722	-63.31679
321	321	Variable Inter-Compression Analysis Between the Repeated Calibrations  (t1)  of 48 Catheters in the Original and the Compressed/Decompressed  (CR 6, 10 and 16)  Image Series and the First Calibrations  (t0)  in the Original Image Series legend	7	17	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	24.522154	10.06398	139.27127	-122.63882	-13.841668
322	322	Pulse, Systolic Blood Pressure, End-Tidal Carbon Dioxide Concentration and Arterial Oxygen Saturation at Rest, at 3 Minutes of Exercise, at 6 Minutes of Exercise and at Peak Exercise With Placebo and Dihydrocodeine	5	19	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	2.2038648	1.6995275	-65.64205	56.817825	-145.16666
323	323	Diagnostic Accuracy of Whole-Heart Coronary Magnetic Resonance Angiography to Detect Stenoses of 50% in 113 Patients Who Completed Acquisition of Coronary Magnetic Resonance Data	5	16	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	14.757887	-14.1602745	-88.11581	139.5768	-4.5342727
324	324	Analysis of Significance and Prognostic Value of Systolic Blood Pressure, Diastolic Blood Pressure and Mean Arterial Blood Pressure Obtained During Dobutamine Infusion  a	5	15	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	18.277395	-7.406608	51.829422	105.34339	-133.1817
325	325	Analysis of the Influence of Coronary Diameter, Image Quality, and Coronary Calcium of the Diagnostic Performance of 64-Slice CTCA for the Detection of 50% Stenosis on QCA in the Per-Segment Analysis  (95% CI)	5	16	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	12.725682	-13.636144	-65.56135	101.2099	9.719908
326	326	Cutpoints for Electron Beam Computed Tomographic Coronary Calcium Scores for Sensitivity of 90% and Associated Specificity and for Electron Beam Computed Tomographic Quantified Coronary Calcium Scores for Specificity of 90% and Associated Sensitivity as a Function of Decade of Associated Maximal Angiographic Lumen Stenoses	5	20	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	18.263153	-11.805066	0.91007364	140.91788	-8.835679
327	327	Relative Coronary Flow Reserves for Adenosine and Papaverine and Volumetric Coronary Flow Reserve for Acetylcholine in Five Patients with the Adenosine Defect and Twenty-Four Control Subjects	5	16	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	8.116729	-14.255277	-164.17436	77.57585	4.214057
328	328	PET Flow and Glucose Uptake, Percent MIBI Uptake, Ventricular Function and Percent Fibrosis in Anterior Wall Biopsy Specimen	5	12	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	0.92234796	2.4525878	-24.048565	94.787704	-133.63472
329	329	Relationship Between Coronary Artery Lesions and Perfusion Defects on Thallium-201 Single Photon Emission Computed Tomography	5	12	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	14.438507	-9.01826	-23.410925	-167.84586	-72.251495
330	330	Intensity of Single-Photon Emission Computed Tomographic Perfusion Defects, Wall Motion Abnormalities and Contrast Effects on Patients in Each Randomized Dosage Group legend	5	13	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	14.035401	-7.8462534	-47.814793	139.96758	-121.97893
331	331	Comparison Between Intravenous Electron-Beam Coronary Angiography and Selective Coronary Angiography in 221 Segments Comprising the Proximal and Mid Major Coronary Arteries  (eight-segment model)  in 28 Patients  legend	5	19	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	17.215403	-13.798287	-123.10319	115.473236	43.985157
332	332	Diagnostic Performance of SPECT, CMR, and PET Perfusion Imaging on Patient and Coronary Artery Territory Basis	5	10	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	11.199837	-11.417966	-65.94152	-69.88867	147.91248
333	333	Results: Detection of Significant  (50%)  Stenoses With 16-Row Multislice Spiral Computed Tomography Coronary Angiography	5	10	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	15.033729	-12.220037	-138.48447	-32.33742	99.71121
334	334	Quantitative Measurements of Wall Thickness, Simulated Wall Motion and Simulated Wall Thickening Using the Variable Thickness Heart Phantom	5	12	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	16.341259	-3.44415	141.80598	-69.43545	-100.816895
335	335	Detection of Significant Coronary Stenoses by Electron Beam Computed Tomography Versus Coronary Angiography for 267 Analyzed Segments	5	12	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	16.104086	-12.861613	52.04419	-4.213051	-172.54662
336	336	Results of Quantitative Computerized Digital Analysis of Micro-CT Images by Normal and the Balloon-injured Coronary Arteries	5	12	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	10.766769	-8.5096	-106.924736	53.96993	-16.56115
337	337	Correlation of Single-Photon Emission Computed Tomography  (SPECT)  With Harmonic Myocardial Contrast Echocardiography in the Triggered Mode, According to the Correlation of SPECT with Wall Motion Analysis  (After Exclusion of Nondiagnostic Studies)  legend	5	22	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	15.220837	-6.304289	-44.745365	121.53957	-91.124535
338	338	Performance Indexes of CTCA and SPECT/CTCA for Detection of Hemodynamically Significant Coronary Lesions in 170 Segments in 44 Patients	5	12	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	12.436461	-12.191592	-84.35437	88.42592	-18.020178
339	339	Results of Magnetic Resonance Imaging Parameters and uptake by Positron Emission Tomography, According to Wall Motion	5	11	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	14.282077	-4.574947	-30.729876	86.97444	-88.56907
340	340	Mitral Inflow, Pulmonary Venous Flow and Mitral Annulus Velocity in 59 Normal Volunteers	5	10	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	1.3399669	0.4743803	-154.71355	37.56083	-39.280308
341	341	Diagnostic Performance of RT-MCE and SPECT to Detect Significant Coronary Artery Disease in Individual Vascular Territories	5	8	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	11.255153	-11.480495	14.0347	-5.3502665	-121.70335
342	342	Diagnostic Accuracy of Coronary CTA for the Detection of Acute Coronary Syndrome and Myocardial Infarction During Index Hospitalization Among Patients With Acute Chest Pain Based on the Presence of Any Coronary Plaque or the Presence of Coronary Artery Stenosis  (>50% Luminal Narrowing)	5	17	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	11.473344	-15.574381	-85.650764	84.9493	36.676353
343	343	Results of Coronary Artery Segment Classification and Stenosis Assessment by Contrast-enhanced Magnetic Resonance Coronary Angiography Compared With Conventional Invasive Angiography  (n = 350)  legend	5	18	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	16.511297	-14.5185585	-103.92299	133.40457	27.773453
344	344	Diagnostic Performance of Multi-Slice Computed Tomography Coronary Angiography to Detect 50% Stenoses	5	10	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	14.30427	-12.8553915	-63.466003	121.63286	-14.03191
345	345	Comparison of MCE, SPECT, Wall Motion and the Combination of MCE and Wall Motion With Results of Coronary Angiography: Analysis by Patients  (n = 44)  legend	5	13	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	15.483063	-4.6856933	83.51181	-3.7712946	165.38042
346	346	Per-Vessel Diagnostic Accuracy of CTA+ TAG320, CTA+ CTP, and MDCT-IP Methods in 97 Vessels	5	6	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	10.604971	-4.420909	47.431534	50.413033	136.25041
347	347	Mean Myocardial Perfusion Measures Across Number of Coronary Arteries Containing Calcium  (Coronary Artery Calcium Score >0 in the Respective Artery)  in Subjects With No Clinical Coronary Heart Disease From The Multi-Ethnic Study of Atherosclerosis	5	17	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	12.000727	-10.096982	-129.531	108.543144	-11.988118
348	348	Comparison of Superior Vena Cava Peak Forward and Reverse Flow Velocity in Chronic Obstructive Pulmonary Disease and Constrictive Pericarditis  legend	5	16	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	-7.5864177	12.486973	-116.70494	17.676079	-32.121887
349	349	Accuracy of Multislice Computed Tomography for the Detection of Significant Coronary Plaque    : Comparison With IVUS for the Entire Region of Interest and for its 5-mm Subsegments	5	11	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	15.527702	-11.277455	-31.043537	119.783585	-43.46372
350	350	Overview of Used Risk Scores: Risk Factors Used in CHA2DS2-VASc Risk Score and CHADS2 Risk Score	3	11	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-11.541768	-5.8549	67.80544	3.1204135	110.887955
351	351	Comparison of CHA2DS2-VASc and CHA2DS2-VASc-R Scores in Predicting Stroke: Relative Hazard Associated With 1-Point Increase in Stroke Risk Score, and C-Statistic	3	13	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-12.575983	-10.787209	121.765976	41.740906	91.88596
352	352	Comparison of CHA2DS2-VASc and CHA2DS2-VASc-R Scores in Predicting Stroke: Relative Hazard Associated With 1-Point Increase in Stroke Risk Score, and C-Statistic	3	13	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-12.575983	-10.787209	121.765976	41.740906	91.88596
353	353	Hazard of Stroke by Race/Ethnicity, Relative to White Patients, After Controlling for CHA2DS2-VASc Score  (Model 1)  and CHA2DS2-VASc Score Plus Anticoagulant Use  (Model 2)	3	16	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-14.4086	-13.172574	113.318924	76.18369	64.627594
354	354	Hazard of Stroke by Race/Ethnicity, Relative to White Patients, After Controlling for CHA2DS2-VASc Score  (Model 1)  and CHA2DS2-VASc Score Plus Anticoagulant Use  (Model 2)	3	16	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-14.4086	-13.172574	113.318924	76.18369	64.627594
355	355	ORunadjusted and ORadj-2 of morbidity at 30 days for patients with anaemia or risk factors and anaemia and risk factors, compared with reference populations of patients with neither anaemia nor risk factors	3	18	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-8.367199	-24.744467	29.900482	-182.55283	-22.906118
356	356	7-day risk of stroke stratified according to ABCD score at first assessment in all referrals with suspected TIA to OXVASC and risk of stroke before scheduled clinic appointment in all referrals with suspected TIA to the non-OXVASC hospital-referred weekly TIA clinic	3	14	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-13.809794	-5.3641276	56.190136	-2.1416948	70.15722
357	357	ORunadjusted and ORadj-2 of mortality at 30 days for patients with anaemia or risk factors and anaemia and risk factors, compared with reference populations of patients with neither anaemia nor risk factors	3	17	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-8.368193	-24.753307	-1.7188191	184.6613	6.697591
358	358	Association of Age, Sex, and Race/Ethnicity With ABI Category, and Age-, Sex-, and Race/Ethnicity-Adjusted Distributions of Risk Factors by ABI Category	3	10	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-8.719378	-2.2168057	66.20976	32.706554	47.19477
359	359	Association of TG or TG Genetic Risk Score With CAC 75th Percentile in the FHS	3	5	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-1.5323508	-0.45605484	-45.342915	5.222817	-136.11612
360	360	Relative Risk of Incident CAC and Mean Change in CAC Score With Varying FRS and RRS Groups According to Low- and High-Risk Groups Classified by FRS and RRS, Respectively	3	7	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-10.033283	-4.14891	39.793648	3.3800516	37.90313
361	361	Pooled analysis of the early risk of recurrent vascular events, given per time period after randomisation, in trials of aspirin versus control in secondary prevention after transient ischaemic attack and ischaemic stroke	3	19	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-8.648508	4.5258822	-0.7455109	36.26992	104.87133
362	362	Risk of Ischemic Stroke in Patients with an ATRIA Score of 0 to 5, Stratified on the Basis of Their CHA2DS2-VASc Scores	3	10	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-12.804195	-7.740079	-27.261515	-28.960117	-167.39748
363	363	Western Aphasia Battery  (WAB)  subtest scores before and after resection for patients with dominant hemispheric tumour who were dysphasic  (aphasia quotient <937)  before resection	3	13	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-16.00422	-22.061998	-50.182793	-67.02139	-3.8868308
364	364	Risk of Ischemic Stroke in AF Female Patients  (CHA2DS2-VASc Score of 2: Female Plus 1 Additional Stroke Risk Factor)	3	13	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-11.378983	-8.033439	85.8327	20.767525	80.184364
365	365	Western Aphasia Battery  (WAB)  summary scores before and after resection for patients with dominant hemispheric tumour who were dysphasic  (aphasia quotient <937)  before resection	3	13	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-16.007664	-21.920324	-59.795033	87.50564	160.7116
366	366	Severity and duration of upper-respiratory-tract  (URT)  and lower-respiratory-tract  (LRT)  symptoms associated with rhinovirus infection	1	7	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-2.842377	0.44797269	-32.616856	30.578432	-146.92474
367	367	Statistical associations  (p<10107)  between Illumina SNPs and circulating concentrations of LDL cholesterol in a genome-wide meta-analysis of three UK study populations consisting of up to 4337 participants	3	15	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-26.286425	-9.836836	-29.341602	-10.837977	-116.72597
368	368	c statistics  (with 95% CI)  for early stroke discrimination with ABCD2, ABCD2-I, and ABCD3-I scores at each timepoint after transient ischaemic attack	3	12	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-5.7967105	5.075883	58.589005	93.18553	126.082886
369	369	Association of Lipid Measures or Genetic Risk Scores With CAC 75th Percentile in the Pooled FHS Offspring and Third-Generation Cohorts  (n = 3,110)	3	11	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-1.8467045	-0.3374481	17.65907	56.442066	8.25159
370	370	Ischemic Stroke Event Rates Stratified by the Sum of Points for ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores	3	11	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-12.712176	-7.7581425	79.29875	44.975903	107.65718
371	371	Randomised controlled trials included in the systematic review and network meta-analysis	3	9	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	4.2149878	-2.1541417	-11.291568	53.14961	-22.227922
372	372	Statistical associations  (p<10107)  between Affymetrix SNPs and circulating concentrations of LDL cholesterol in a genome-wide meta-analysis of five study populations consisting of up to 11685 participants	3	14	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-26.345076	-9.630755	-59.64964	-19.275652	34.950226
373	373	Pooled analysis of the effect of any aspirin versus control in secondary prevention after TIA and ischaemic stroke on the early risk of any recurrent ischaemic stroke and on disabling or fatal ischaemic stroke stratified by the nature of the presenting event  (TIA and minor stroke vs major stroke)  and by time from presenting event to randomisation  (14 days vs >14 days)	3	33	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-9.190104	5.256001	11.063636	38.82091	129.07402
374	374	Prevalence of Solo and Combination Antiplatelet Prescription in AF Patients at Intermediate to High Risk of Stroke, Stratified by Prescription of Aspirin Versus OAC in the Overall CHADS2 Score2 and CHA2DS2-VASc Score2 Cohorts and Subcohorts of Patients With and Without Any Coronary Heart Disease Risk Equivalent	3	23	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-14.166582	-7.5814147	101.99712	17.34543	128.07372
375	375	Adjuvant radiotherapy received  (within 3 months after surgery) , nodes removed, nodal status, and external-beam radiotherapy  (EBRT)  received in node-positive patients by risk group defined according to ASTEC radiotherapy eligibility	7	13	patient(57),outcom(24),hospit(22),clinic(21),acut(21),legend(20),myocardi(18),infarct(17),therapi(13),versus(11)	-11.412279	2.0937006	1.2503531	84.69108	156.62704
376	376	Distribution of WHODAS disability scores by dementia status and site, and the effects of dementia  (main effect of 10/66 dementia, modified by DSM-IV dementia)  on WHODAS score	3	16	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-11.3045635	-2.0802877	169.0436	10.195723	76.65014
377	377	Drug Prescription Distribution Among Responders by Haplotype Arg389Arg-Ser49Ser  (n = 85)  and Arg389Gly-Ser49Ser  (n = 97)	3	3	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	0.45688215	-0.42024395	2.681731	-7.101369	-35.93095
378	378	Vascular risk factors and retinal vascular signs in patients with lacunar and other ischaemic stroke	3	8	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-8.0313	1.2724366	14.424407	19.640352	66.61776
379	379	Availability of data from randomised trials that began before 1990 of adjuvant tamoxifen versus no adjuvant tamoxifen	3	8	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	2.8447735	-15.050918	-5.627294	75.21145	-51.499733
380	380	Western Aphasia Battery  (WAB)  summary scores before and after resection for patients whose language was classified as normal  (aphasia quotient 938)  before resection	3	12	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-16.004501	-21.283646	-78.83349	-63.13225	-0.5666287
381	381	Imputed SNPs showing genome-wide statistical association  (p<10107)  with circulating concentrations of LDL cholesterol; meta-analysis of four study populations consisting of up to 9988 participants	3	16	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-26.715538	-9.845679	-82.6593	-24.778315	27.089422
382	382	Risk of transient ischaemic attack according to use of HRT and identified risk factors in women aged 4564 years	3	8	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-6.545608	2.4663851	-43.655315	-180.19171	56.41101
383	383	Prevalence Rates of Major Cardiovascular Risk Factors in Patients With Familial P-CAD and Their Respective Age- and Gender-Matched Control Subjects, According to Parental History of CAD in Patients with Familial P-CAD *	3	12	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-5.723863	-4.897399	54.74481	-61.201775	143.06079
384	384	Independent contributions to the risk of a second ischaemic stroke for prothrombotic risk factors, antithrombotic treatment, and stroke subtypes	3	11	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-8.98136	2.2392988	53.99409	47.497784	79.45776
385	385	Design of randomised trials of unfractionated heparin compared with placebo or untreated control in acute coronary syndrome without ST elevation	5	6	coronari(47),arteri(17),patient(16),wall(15),detect(15),flow(13),diagnost(13),angiographi(13),comput(12),tomographi(12)	5.0413733	-3.0531032	-34.780964	53.145466	-39.121643
386	386	Discrimination between benign and malignant thyroid lesions by CD44v6 and galectin-3 immunodetection on fresh cytological material from preoperative fine-needle aspiration	2	9	cancer(27),year(25),health(15),incid(14),surviv(13),develop(13),standardis(13),ratio(13),type(12),countri(12)	-7.9185452	-8.794911	-84.29969	19.077	-151.90913
387	387	Risk of ischaemic stroke subtypes  *   associated with risk factors	3	7	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-8.195292	2.0464401	39.41237	28.017107	73.18589
388	388	Germline BRCA mutation status according to tumour BRCA mutation status	3	9	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-5.8606873	-10.631134	136.95325	-24.903267	122.448654
389	389	Multivariable Logistic Regression Predicting the Likelihood of CAD According to Quartiles of LBP Levels, Markers of Systemic Inflammation, and Established Cardiovascular Risk Factors	3	6	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	3.6802459	2.397811	85.180336	105.0143	32.065845
390	390	Evaluating the Predictive Ability of the HAS-BLED Score Versus CHADS2 or CHA2DS2-VASc Score for the Detection of MajorBleeding Using C-Statistics, Relative NRI, and IDI Indexes	3	10	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-14.126278	-9.806828	106.86301	72.28476	117.42097
391	391	Description of haemostatic gene polymorphisms in this review and their associated intermediate phenotypes	3	8	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-0.82885724	-1.248168	20.534527	42.831665	-24.499979
392	392	Risk of intracerebral haemorrhage according to use of HRT and identified risk factors in women aged 4564 years	3	6	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-6.34518	2.326761	58.13442	-31.724562	45.956997
393	393	Prevalence of different risk factors in cryptogenic versus other transient ischaemic attack and ischaemic stroke subtypes	3	12	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-8.106144	3.32161	24.59886	40.391216	92.23557
394	394	Women with hormone-receptor-positive tumours and who did not report either symptom at trial entry with vasomotor symptoms or joint symptoms at the 3-month follow-up visit according to treatment group	1	11	intervent(19),modern(13),women(12),method(12),estim(12),level(11),incom(11),high(9),countri(9),region(8)	-13.834719	11.446442	-21.5183	-108.13588	-3.939318
395	395	Overview of Used Risk Scores: Risk Factors Used in ATRIA Risk Score	3	8	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-11.513042	-5.7767076	47.424603	9.781525	102.46
396	396	Respiratory-chain enzyme activity in circulating lymphocytes of patients 1 and 3 and of 163 controls	3	5	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-0.31842196	-3.302085	-41.48411	146.77376	13.8522835
397	397	SLC6A3 mutations identified in patients with dopamine transporter deficiency syndrome	3	7	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-1.2402844	-3.6299672	11.079831	-15.259968	-79.88159
398	398	Relative Risk of Incident CAC Associated With Increasing Risk Categories According to FRS and RRS Classification	3	8	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-8.770753	-3.6534352	2.9173245	-5.1256485	-190.84819
399	399	Mean Change in CAC Score  (Agatston Units)  Associated With Increasing Risk Categories According to FRS and RRS Classification	3	6	risk(49),score(37),stroke(27),associ(19),factor(19),patient(17),ischaem(14),vasc(14),accord(13),studi(12)	-8.522668	-4.096446	35.408318	47.0978	37.208458
